Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Upregulated expression of Annexin II is a prognostic marker for patients with gastric cancer

Authors: Qi Zhang, Zaiyuan Ye, Qiong Yang, Xujun He, Huiju Wang, Zhongsheng Zhao

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

The role of annexin II in the development and progression of gastric cancer was explored.

Methods

Real-time PCR was conducted to detect annexin II and S100A6 mRNA expression. Protein expressions of annexin II and S100A6 were also examined by immunohistochemistry in 436 clinicopathologically characterized gastric cancer cases.

Results

The expression of annexin II and S100A6 mRNA differ significantly among gastric tumor tissue and matched non-cancerous gastric mucosa. Protein levels of annexin II and S100A6 were up-regulated in gastric cancer compared with adjacent non-cancerous tissues. High expression of annexin II correlated with age, location of tumor, size of tumor, differentiation, histological type, depth of invasion, vessel invasion, lymph node metastasis, distant metastasis and Tumor, Node, Metastasis (TNM) stage, and also with expression of S100A6. Further multivariate analysis suggested that expression of annexin II and S100A6 were independent prognostic indicators for gastric cancer.
Cumulative five-year survival rates of patients with high expression of both annexin II and S100A6 was significantly lower than those with low expression of both.

Conclusion

Expression of annexin II in gastric cancer was significantly associated with depth of invasion, lymph node metastasis and distant metastasis, TNM stage, high S100A6 expression, and poor prognosis. Annexin II and S100A6 proteins could be useful prognostic marker to predict tumor progression and prognosis in gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Sentani K, Oue N, Sakamoto N, Anami K, Naito Y, Aoyagi K, Sasaki H, Yasui W: Upregulation of connexin 30 in intestinal phenotype gastric cancer and its reduction during tumor progression. Pathobiology. 2010, 77: 241-248. 10.1159/000314966.CrossRefPubMed
2.
Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL, Zhan WH, Wen JM, Guan XY: Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009, 40: 1790-1797. 10.1016/j.humpath.2009.07.005.CrossRefPubMed
3.
Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009, 15: 1821-1829. 10.1158/1078-0432.CCR-08-2138.CrossRefPubMed
4.
Alberts SR, Cervantes A, van de Velde CJ: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003, 14 (Suppl 2): ii31-ii36.PubMed
5.
Tsugane S, Sasazuki S: Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer. 2007, 10: 75-83. 10.1007/s10120-007-0420-0.CrossRefPubMed
6.
Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2010, 16: 260-268. 10.1158/1078-0432.CCR-09-1247.CrossRefPubMed
7.
Wang CS, Chao TC, Jan YY, Jeng LB, Hwang TL, Chen MF: Benefits of palliative surgery for far-advanced gastric cancer. Chang Gung Med J. 2002, 25: 792-802.PubMed
8.
Seemann J, Weber K, Gerke V: Annexin I targets S100C to early endosomes. FEBS Lett. 1997, 413: 185-190. 10.1016/S0014-5793(97)00911-3.CrossRefPubMed
9.
Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, Schirmacher P, Brand K: Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract. 2011, 207: 8-14. 10.1016/j.prp.2010.09.007.CrossRefPubMed
10.
Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, Hajjar KA, Tsirka SE: Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci. 2011, 31: 14346-14360. 10.1523/JNEUROSCI.3299-11.2011.PubMedCentralCrossRefPubMed
11.
Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC: Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 2006, 81: 146-156. 10.1016/j.yexmp.2006.03.003.CrossRefPubMed
12.
Diaz VM, Hurtado M, Thomson TM, Reventós J, Paciucci R: Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004, 53: 993-1000. 10.1136/gut.2003.026831.PubMedCentralCrossRefPubMed
13.
Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C: Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 2009, 90: 177-185. 10.1007/s12185-009-0356-8.CrossRefPubMed
14.
Ranson M, Andronicos NM: Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003, 8: s294-s304. 10.2741/1044.CrossRefPubMed
15.
Mussunoor S, Murray GI: The role of annexins in tumour development and progression. J Pathol. 2008, 216: 131-140. 10.1002/path.2400.CrossRefPubMed
16.
Kwaan HC: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992, 11: 291-311. 10.1007/BF01307184.CrossRefPubMed
17.
Sharma MC, Sharma M: The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des. 2007, 13: 3568-3575. 10.2174/138161207782794167.CrossRefPubMed
18.
Rezvanpour A, Shaw GS: Unique S100 target protein interactions. Gen Physiol Biophys. 2009, 28: F39-F46. 10.4149/gpb_2009_01_39.CrossRefPubMed
19.
Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, Larre S, Champigneuille J, Fromont G, Cussenot O, Hamdy FC: S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer. 2004, 91: 739-744.PubMedCentralCrossRefPubMed
20.
Lee HS, Lee HK, Kim HS, Yang HK, Kim WH: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003, 200: 39-46. 10.1002/path.1288.CrossRefPubMed
21.
Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH: MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001, 92: 1427-1434. 10.1002/1097-0142(20010915)92:6<1427::AID-CNCR1466>3.0.CO;2-L.CrossRefPubMed
22.
Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A, Hong K, Settnek S, Gupta A, Buetow K, Hewitt S, Travis WD, Jen J: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 2004, 10: 4314-4324. 10.1158/1078-0432.CCR-03-0489.CrossRefPubMed
23.
Song LB, Liao WT, Mai HQ, Zhang HZ, Zhang L, Li MZ, Hou JH, Fu LW, Huang WL, Zeng YX, Zeng MS: The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett. 2006, 242: 258-265. 10.1016/j.canlet.2005.11.013.CrossRefPubMed
24.
Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, Takayama T, Uchida H, Kamada K, Naito A, Hirao S, Nakajima Y: Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001, 21: 1339-1345.PubMed
25.
Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y: Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer. 2001, 92: 1419-1426. 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J.CrossRefPubMed
26.
Zimmermann U, Woenckhaus C, Pietschmann S, Junker H, Maile S, Schultz K, Protzel C, Giebel J: Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch. 2004, 445: 368-374. 10.1007/s00428-004-1103-4.CrossRefPubMed
27.
Liu JW, Shen JJ, Tanzillo-Swarts A, Bhatia B, Maldonado CM, Person MD, Lau SS, Tang DG: Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene. 2003, 22: 1475-1485. 10.1038/sj.onc.1206196.CrossRefPubMed
28.
Qi YJ, He QY, Ma YF, Du YW, Liu GC, Li YJ, Tsao GS, Ngai SM, Chiu JF: Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem. 2008, 104: 1625-1635. 10.1002/jcb.21727.CrossRefPubMed
29.
Pena-Alonso E, Rodrigo JP, Parra IC, Pedrero JM, Meana MV, Nieto CS, Fresno MF, Morgan RO, Fernandez MP: Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett. 2008, 263: 89-98. 10.1016/j.canlet.2007.12.029.CrossRefPubMed
30.
Lokman NA, Ween MP, Oehler MK, Ricciardelli C: The role of annexin A2 in tumorigenesis and cancer progression. Canc Microenviron. 2011, 4: 199-208. 10.1007/s12307-011-0064-9.CrossRef
31.
Yeatman TJ, Updyke TV, Kaetzel MA, Dedman JR, Nicolson GL: Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells. Clin Exp Metastasis. 1993, 11: 37-44. 10.1007/BF00880064.CrossRefPubMed
32.
Yan GR, Ding W, Xu SH, Xu Z, Xiao CL, Yin XF, He QY: Characterization of phosphoproteins in gastric cancer secretome. OMICS. 2011, 15: 83-90. 10.1089/omi.2010.0056.CrossRefPubMed
33.
Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V: Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem. 2005, 280: 20833-20841. 10.1074/jbc.M412653200.CrossRefPubMed
34.
Frances R, Tumang JR, Rothstein TL: Extreme skewing of annexin II and S100A6 expression identified by proteomic analysis of peritoneal B-1 cells. Int Immunol. 2007, 19: 59-65.CrossRefPubMed
35.
Nedjadi T, Kitteringham N, Campbell F, Jenkins RE, Park BK, Navarro P, Ashcroft F, Tepikin A, Neoptolemos JP, Costello E: S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer. 2009, 101: 1145-1154. 10.1038/sj.bjc.6605289.PubMedCentralCrossRefPubMed
36.
Waisman DM: Annexin II tetramer: structure and function. Mol Cell Biochem. 1995, 149–150: 301-322.CrossRefPubMed
37.
38.
Matsumoto T, Murao S, Kito K, Kihana T, Matsuura S, Ueda N: Modulation of S-100 genes response to growth conditions in human epithelial tumor cells. Pathol Int. 1997, 47: 339-346. 10.1111/j.1440-1827.1997.tb04506.x.CrossRefPubMed
Metadata
Title
Upregulated expression of Annexin II is a prognostic marker for patients with gastric cancer
Authors
Qi Zhang
Zaiyuan Ye
Qiong Yang
Xujun He
Huiju Wang
Zhongsheng Zhao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-103

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue

Case report

A pure invasive cribriform carcinoma of the breast with bone metastasis if untreated for thirteen years: a case report and literature review

Case report

Primary malignant non-Hodgkin’s lymphoma of the breast: a study of seven cases and literature review

Research

The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease

Technical innovations

Total thyroidectomy with ultrasonic dissector for cancer: multicentric experience

Research

Prognostic significance of tumor markers in T4a gastric cancer

Research

A comparative analysis of toluidine blue with frozen section in oral squamous cell carcinoma